Matinas BioPharma
MTNB
66 hedge funds and large institutions have $33.5M invested in Matinas BioPharma in 2021 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 20 increasing their positions, 8 reducing their positions, and 13 closing their positions.
150% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 8
8% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 13
0% more funds holding
Funds holding: 66 → 66 (0)
6.48% less ownership
Funds ownership: 18.47% → 11.99% (-6.5%)
74% less capital inflows, than outflows
Capital inflows: $3.15M | Capital outflows: $12.3M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sargent Investment Group
Bethesda,
Maryland
|
+$907K |
| 2 |
Arkadios Wealth Advisors
Atlanta,
Georgia
|
+$905K |
| 3 |
Virtu Financial
New York
|
+$199K |
| 4 |
Courage Capital Management
Nashville,
Tennessee
|
+$173K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$159K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Boxer Capital Management
San Diego,
California
|
-$8.9M |
| 2 |
GSA Capital Partners
London,
United Kingdom
|
-$812K |
| 3 |
Victory Capital Management
San Antonio,
Texas
|
-$769K |
| 4 |
Renaissance Technologies
New York
|
-$472K |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$465K |
MTNB Hedge Fund Activity: Q3 2021 in Review
66 of the 5,730 institutional investors tracked by Wall St. Rank reported a position in Matinas BioPharma (MTNB) for Q3 2021, worth a combined $33.5M — up 14% from $29.2M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new MTNB positions and 13 closed out — a net gain of 1 holder — while 20 added to existing stakes and 8 trimmed.
The largest buyer was Sargent Investment Group, adding an estimated $907K. The largest seller was Boxer Capital Management, exiting entirely with an estimated $8.9M sold.
- 66 institutional investors held Matinas BioPharma (MTNB) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $33.5M of Matinas BioPharma stock for Q3 2021, up 14% quarter-over-quarter.
- 14 funds opened new Matinas BioPharma positions in Q3 2021 and 13 closed out, a net change of +1 holder.
- The largest Matinas BioPharma buyer in Q3 2021 was Sargent Investment Group, an estimated $907K added.
- The largest Matinas BioPharma seller in Q3 2021 was Boxer Capital Management, an estimated $8.9M sold.
Based on aggregated 13F filings for Q3 2021.